Designing Around the Moat: How Generic Developers Can Use Secondary Formulation Patents to Win (Not Just Survive)
In generic drug development, the real fight rarely happens at the finish line. It happens earlier—when a brand’s “moat” is less about the …

Patent cliffs aren’t just a legal event—they’re a supply-chain stress test.
If you’re in pharma operations, procurement, or planning, you already know the headline: blockbuster exclusivities end, generics flood in, and margins shift overnight. But th…

Pharma’s next IP battleground isn’t the molecule—it’s the formulation.
For years, the industry has treated “designing around” as a chemistry problem: tweak the active ingredient, change the route, move on. But in 2026, the more common—and more expensiv…

Drug patents aren’t just about the active ingredient. They’re about the how.
Most people read drug patent claims and stop at the molecule—what the drug is. But the real competitive intelligence often hides in the “boring” details: excipients, formula…

Generic makers don’t “wait” for exclusivity—they engineer it.
In the Paragraph IV world, the 180-day exclusivity clock doesn’t just measure time. It measures execution: legal strategy, manufacturing readiness, regulatory timing, and the ability to ou…

The Patent Dance Is Over. The Litigation Playbook Is the New Competitive Edge.
If you’re a biologics innovator—or a biosimilar applicant—you already know the choreography: the BPCIA “patent dance,” the exchanges, the timelines, the strategic disclosure…

Big Pharma loves to talk about innovation. But the real competitive edge in drug development is increasingly hiding in plain sight: the data that sits before the headlines—patent timelines, exclusivity cliffs, and the supply-chain realities that determ…

Patent cliffs don’t just reshape pipelines—they reshape budgets.
For procurement leaders and supply chain teams, the “patent cliff” moment is often treated like a downstream event: a forecast, a contract renegotiation, a scramble for alternative supp…